secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001615219-25-000135
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius amends merger deal with Decoy; sets preferred conversion floor at $3.75
--------------------------------------------------------------------------------

- Fifth Amendment to Merger Agreement sets initial conversion price at $10.50/share for Series A & B Preferred.
- Price protection adjusted using spread between $10.50 baseline and any dilutive subsequent financing.
- Floor price of $3.75/share set as lowest conversion price in price protection calculations.
- Series B Preferred redemption price changed to $10.50 multiplied by 1,000 per share.
- All other Merger Agreement terms remain in full force and effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/0001615219-25-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/flks-20250917.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer